We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

XRO:ASXXero Limited Analysis

Data as of 2026-08-01 - not real-time

A$70.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Xero Limited is trading around $70, just below its 20‑day simple moving average and well above the 200‑day average, indicating a short‑term pullback within a longer‑term bearish backdrop. The 14‑day RSI hovers near the 50‑point neutral zone and the MACD histogram has turned positive, suggesting a modest bullish momentum despite the overall bearish trend direction. Volume has been increasing, providing better liquidity than the recent three‑month average, while the 30‑day realized volatility exceeds 50%, underscoring a highly erratic price environment. Recent headlines note a two‑thirds loss in market value over the past year, yet a recent 7% rebound aligns with the technical bounce seen on the day.
Fundamentally, revenue is expanding at a robust 40% year‑over‑year and gross margins remain near 84%, but profitability is thin with a trailing EPS of –$0.16 and a forward EPS of just under $2. The DCF‑derived fair value of roughly $43 places the current price well above intrinsic estimates, flagging the stock as overvalued. No dividend is paid, eliminating income‑based appeal. The company’s diversified geographic footprint and low beta temper some risk, but the combination of high volatility, large historical drawdown, and bearish technical stance elevates overall risk considerations.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near short‑term support with limited upside to next resistance
  • Positive MACD histogram amid overall bearish trend
  • Increasing volume providing better short‑term liquidity

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and high gross margins
  • Forward EPS turning positive, indicating earnings recovery
  • Market overreaction reflected in price versus DCF fair value

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustained growth prospects from AI‑enabled product suite
  • Elevated valuation multiples relative to industry peers
  • Low beta and diversified geographic exposure reducing systemic risk

Key Metrics & Analysis

Financial Health

Revenue Growth40.80%
Profit Margin6.08%
P/E Ratio35.3
ROE4.41%
ROA3.38%
Debt/Equity39.33
P/B Ratio2.7
Op. Cash FlowA$933.1M
Free Cash FlowA$221.1M
Industry P/E32.8

Technical Analysis

TrendBearish
RSI50.0
SupportA$61.45
ResistanceA$75.71
MA 20A$69.75
MA 50A$72.54
MA 200A$93.38
MACDBullish
VolumeIncreasing
Fear & Greed Index92.88

Valuation

Fair ValueA$43.52
Target PriceA$127.08
Upside/Downside81.55%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.50
Volatility54.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.